Cargando…

Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration

PURPOSE: We sought to determine if organ preservation (OP) with neoadjuvant chemoradiation (CRT) was feasible in patients with sinonasal cancer determined to require exenteration. MATERIALS AND METHODS: Twenty patients were determined to require exenteration for definitive treatment from 2005 to 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Amsbaugh, Mark J., Yusuf, Mehran, Silverman, Craig, Bumpous, Jeffrey, Perez, Cesar A., Potts, Keven, Tennant, Paul, Redman, Rebecca, Dunlap, Neal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society for Radiation Oncology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066443/
https://www.ncbi.nlm.nih.gov/pubmed/27592515
http://dx.doi.org/10.3857/roj.2016.01739
_version_ 1782460488133640192
author Amsbaugh, Mark J.
Yusuf, Mehran
Silverman, Craig
Bumpous, Jeffrey
Perez, Cesar A.
Potts, Keven
Tennant, Paul
Redman, Rebecca
Dunlap, Neal
author_facet Amsbaugh, Mark J.
Yusuf, Mehran
Silverman, Craig
Bumpous, Jeffrey
Perez, Cesar A.
Potts, Keven
Tennant, Paul
Redman, Rebecca
Dunlap, Neal
author_sort Amsbaugh, Mark J.
collection PubMed
description PURPOSE: We sought to determine if organ preservation (OP) with neoadjuvant chemoradiation (CRT) was feasible in patients with sinonasal cancer determined to require exenteration. MATERIALS AND METHODS: Twenty patients were determined to require exenteration for definitive treatment from 2005 to 2014. Fourteen patients underwent OP and 6 patients received exenteration with adjuvant CRT. Exenteration free survival (EFS), locoregional control (LRC), progression-free survival (PFS), and overall survival (OS) were estimated. RESULTS: Five patients (36%) receiving OP had complete disease response at time of surgery. With a median follow-up of 18.8 months, EFS was 62% at 2 years for patients undergoing OP. At 2 years, there were no significant differences in LRC, PFS or OS (all all p > 0.050) between the groups. Less grade 3 or greater toxicity was seen in patients undergoing OP (p = 0.003). Visual function was preserved in all patients undergoing OP. CONCLUSION: For patients with sinonasal cancer, OP may avoid exenteration, offering similar disease control and improved toxicity.
format Online
Article
Text
id pubmed-5066443
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Korean Society for Radiation Oncology
record_format MEDLINE/PubMed
spelling pubmed-50664432016-10-18 Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration Amsbaugh, Mark J. Yusuf, Mehran Silverman, Craig Bumpous, Jeffrey Perez, Cesar A. Potts, Keven Tennant, Paul Redman, Rebecca Dunlap, Neal Radiat Oncol J Original Article PURPOSE: We sought to determine if organ preservation (OP) with neoadjuvant chemoradiation (CRT) was feasible in patients with sinonasal cancer determined to require exenteration. MATERIALS AND METHODS: Twenty patients were determined to require exenteration for definitive treatment from 2005 to 2014. Fourteen patients underwent OP and 6 patients received exenteration with adjuvant CRT. Exenteration free survival (EFS), locoregional control (LRC), progression-free survival (PFS), and overall survival (OS) were estimated. RESULTS: Five patients (36%) receiving OP had complete disease response at time of surgery. With a median follow-up of 18.8 months, EFS was 62% at 2 years for patients undergoing OP. At 2 years, there were no significant differences in LRC, PFS or OS (all all p > 0.050) between the groups. Less grade 3 or greater toxicity was seen in patients undergoing OP (p = 0.003). Visual function was preserved in all patients undergoing OP. CONCLUSION: For patients with sinonasal cancer, OP may avoid exenteration, offering similar disease control and improved toxicity. The Korean Society for Radiation Oncology 2016-09 2016-09-05 /pmc/articles/PMC5066443/ /pubmed/27592515 http://dx.doi.org/10.3857/roj.2016.01739 Text en Copyright © 2016 The Korean Society for Radiation Oncology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (http://creativecommons.org/licenses/by-nc/4.0) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Amsbaugh, Mark J.
Yusuf, Mehran
Silverman, Craig
Bumpous, Jeffrey
Perez, Cesar A.
Potts, Keven
Tennant, Paul
Redman, Rebecca
Dunlap, Neal
Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration
title Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration
title_full Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration
title_fullStr Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration
title_full_unstemmed Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration
title_short Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration
title_sort organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066443/
https://www.ncbi.nlm.nih.gov/pubmed/27592515
http://dx.doi.org/10.3857/roj.2016.01739
work_keys_str_mv AT amsbaughmarkj organpreservationwithneoadjuvantchemoradiationinpatientswithorbitinvasivesinonasalcancerotherwiserequiringexenteration
AT yusufmehran organpreservationwithneoadjuvantchemoradiationinpatientswithorbitinvasivesinonasalcancerotherwiserequiringexenteration
AT silvermancraig organpreservationwithneoadjuvantchemoradiationinpatientswithorbitinvasivesinonasalcancerotherwiserequiringexenteration
AT bumpousjeffrey organpreservationwithneoadjuvantchemoradiationinpatientswithorbitinvasivesinonasalcancerotherwiserequiringexenteration
AT perezcesara organpreservationwithneoadjuvantchemoradiationinpatientswithorbitinvasivesinonasalcancerotherwiserequiringexenteration
AT pottskeven organpreservationwithneoadjuvantchemoradiationinpatientswithorbitinvasivesinonasalcancerotherwiserequiringexenteration
AT tennantpaul organpreservationwithneoadjuvantchemoradiationinpatientswithorbitinvasivesinonasalcancerotherwiserequiringexenteration
AT redmanrebecca organpreservationwithneoadjuvantchemoradiationinpatientswithorbitinvasivesinonasalcancerotherwiserequiringexenteration
AT dunlapneal organpreservationwithneoadjuvantchemoradiationinpatientswithorbitinvasivesinonasalcancerotherwiserequiringexenteration